John M Gansner
Overview
Explore the profile of John M Gansner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sellier-Leclerc A, Magen D, Shasha-Lavsky H, Simkova E, Devresse A, Guebre-Egziabher F, et al.
Am J Kidney Dis
. 2025 Mar;
PMID: 40086686
No abstract available.
2.
Frishberg Y, Hayes W, Shasha-Lavsky H, Sas D, Michael M, Sellier-Leclerc A, et al.
Front Pediatr
. 2024 Oct;
12:1392644.
PMID: 39355649
Background: Primary hyperoxaluria type 1 (PH1) is a genetic disorder resulting in overproduction of hepatic oxalate, potentially leading to recurrent kidney stones, nephrocalcinosis, chronic kidney disease, and kidney failure. Lumasiran,...
3.
Saland J, Lieske J, Groothoff J, Frishberg Y, Shasha-Lavsky H, Magen D, et al.
Kidney Int Rep
. 2024 Jul;
9(7):2037-2046.
PMID: 39081738
Introduction: Patients with primary hyperoxaluria type 1 (PH1), a genetic disorder associated with hepatic oxalate overproduction, frequently experience recurrent kidney stones and worsening kidney function. Lumasiran is indicated for the...
4.
Clausen V, Cao K, Gansner J, Robbie G, Wu J
Bioanalysis
. 2023 May;
15(9):481-491.
PMID: 37195004
Measurement of plasma oxalate (POx) is challenging, but critical, for management of patients with primary hyperoxaluria type 1. A novel LC-MS/MS assay was developed, validated and used to quantify POx...
5.
Hayes W, Sas D, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc A, et al.
Pediatr Nephrol
. 2022 Aug;
38(4):1075-1086.
PMID: 35913563
Background: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease that causes progressive kidney damage and systemic oxalosis due to hepatic overproduction of oxalate. Lumasiran demonstrated efficacy and safety...
6.
Michael M, Groothoff J, Shasha-Lavsky H, Lieske J, Frishberg Y, Simkova E, et al.
Am J Kidney Dis
. 2022 Jul;
81(2):145-155.e1.
PMID: 35843439
Rationale & Objective: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and...
7.
Hulton S, Groothoff J, Frishberg Y, Koren M, Overcash J, Sellier-Leclerc A, et al.
Kidney Int Rep
. 2022 Mar;
7(3):494-506.
PMID: 35257062
Introduction: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. In the 6-month...
8.
Garrelfs S, Gansner J, Lieske J
N Engl J Med
. 2021 Nov;
385(20):e69.
PMID: 34758265
No abstract available.
9.
Furutani E, Liu S, Galvin A, Steltz S, Malsch M, Loveless S, et al.
Blood Adv
. 2021 Nov;
6(1):297-306.
PMID: 34758064
Shwachman-Diamond syndrome (SDS) is an inherited bone marrow failure syndrome with leukemia predisposition. An understanding of the hematologic complications of SDS with age could guide clinical management, but data are...
10.
Garrelfs S, Frishberg Y, Hulton S, Koren M, ORiordan W, Cochat P, et al.
N Engl J Med
. 2021 Mar;
384(13):1216-1226.
PMID: 33789010
Background: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an...